Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations

Ribociclib (KISQALI), a cyclin‐dependent kinase 4/6 inhibitor approved for the first‐line treatment of HR+/HER2– advanced breast cancer with an aromatase inhibitor, is administered with no restrictions on concomitant gastric pH‐elevating agents or food intake. The influence of proton pump inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Samant, Tanay S., Dhuria, Shyeilla, Lu, Yasong, Laisney, Marc, Yang, Shu, Grandeury, Arnaud, Mueller‐Zsigmondy, Martin, Umehara, Kenichi, Huth, Felix, Miller, Michelle, Germa, Caroline, Elmeliegy, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099197/
https://www.ncbi.nlm.nih.gov/pubmed/29134635
http://dx.doi.org/10.1002/cpt.940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099197/
https://www.ncbi.nlm.nih.gov/pubmed/29134635
http://dx.doi.org/10.1002/cpt.940

Ejemplares similares